All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @my.journey.with.marc on TikTok · 141s|Watch on TikTok

@my.journey.with.marc's GLP-1 side effects claims, fact-checked

My Journey with Marc

TikTok creator

55.4K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) slow gastric emptying and affect brain areas controlling appetite and nausea. Clinical trials consistently show 30-44% of patients experience gastrointestinal side effects regardless of adherence. These effects typically decrease over time but aren't entirely preventable through behavioral changes alone.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @my.journey.with.marc's GLP-1 side effects claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@my.journey.with.marc's GLP-1 side effects claims, fact-checked" from My Journey with Marc. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) slow gastric emptying and affect brain areas controlling appetite and nausea.

The reason this review is not generic is the source wording and the canonical claim label "glp1 glp1 side effects on mounjaro or wegovy here s the most." In this clip, the useful excerpt is: "side effects on or ." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide caused nausea in 31% of patients at 15mg in the SURMOUNT-1 trial despite careful dose escalation protocols
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) slow gastric emptying and affect brain areas controlling appetite and nausea.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) slow gastric emptying and affect brain areas controlling appetite and nausea. Clinical trials consistently show 30-44% of patients experience gastrointestinal side effects regardless of adherence. These effects typically decrease over time but aren't entirely preventable through behavioral changes alone.
  • 44% of people taking 1.0mg semaglutide in the SUSTAIN 1 trial experienced nausea, showing side effects aren't primarily user errors
  • Tirzepatide caused nausea in 31% of patients at 15mg in the SURMOUNT-1 trial despite careful dose escalation protocols

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • 44% of people taking 1.0mg semaglutide in the SUSTAIN 1 trial experienced nausea, showing side effects aren't primarily user errors
  • Tirzepatide caused nausea in 31% of patients at 15mg in the SURMOUNT-1 trial despite careful dose escalation protocols
  • GLP-1 medications slow gastric emptying as part of their mechanism, making some digestive side effects unavoidable
  • Gradual dose increases starting at 0.25mg semaglutide or 2.5mg tirzepatide help minimize but don't eliminate side effects
  • About 7% of semaglutide users and 4.3-8.5% of tirzepatide users discontinue due to side effects in clinical trials
  • Eating smaller meals, limiting alcohol, and staying hydrated can help manage GLP-1 side effects
  • Most gastrointestinal side effects decrease after the first 20 weeks as shown in the STEP 1 trial

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

TikTok creator Marc claims he knows the "most common mistakes" that cause GLP-1 side effects like nausea, vomiting, and diarrhea. But without seeing his specific recommendations, we can't verify if his advice matches what clinical trials actually show about managing these drugs.

What does this video actually claim?

Marc promises to reveal the biggest mistakes people make that supposedly cause side effects with Mounjaro (tirzepatide) and Wegovy (semaglutide). The video's framing suggests these side effects are avoidable user errors rather than expected drug reactions.

This sets up a problematic premise. The most common GLP-1 side effects aren't really "mistakes" people make. They're documented pharmacological effects that happen regardless of how perfectly you follow instructions.

The SUSTAIN 1 trial (Sorli et al., Diabetes Care, 2017) found that 44% of people taking 1.0mg semaglutide experienced nausea. That's not because nearly half the participants made mistakes. It's because semaglutide slows gastric emptying.

What does the science actually show about GLP-1 side effects?

GLP-1 receptor agonists cause predictable gastrointestinal side effects through their mechanism of action. They slow how quickly food leaves your stomach and affect areas of the brain that control nausea.

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) documented side effects with tirzepatide across all dose levels. At 15mg, 31% experienced nausea, 16% had diarrhea, and 12% had vomiting. These rates occurred despite careful dose escalation protocols.

Dose escalation helps reduce side effects but doesn't eliminate them. Most clinical trials start patients at 0.25mg semaglutide or 2.5mg tirzepatide, then increase every four weeks. This gradual approach minimizes but doesn't prevent gastrointestinal issues.

What mistakes do people actually make?

There are real errors that can worsen GLP-1 side effects, though they're not the primary cause. Taking doses too close together or skipping the gradual escalation can increase nausea and vomiting.

Some people also don't adjust their eating patterns. Since GLP-1s slow gastric emptying, eating large meals or high-fat foods can worsen digestive discomfort. Smaller, more frequent meals typically help.

Alcohol can amplify nausea and should be limited, especially during the first few weeks of treatment. Staying hydrated also helps manage side effects, particularly if you're experiencing vomiting or diarrhea.

But let's be clear: even perfect adherence won't eliminate side effects for everyone. The clinical trial data proves this.

What should you actually expect?

Most GLP-1 side effects are temporary and decrease over time. In the STEP 1 trial (Wilding et al., NEJM, 2021), gastrointestinal side effects were most common during the first 20 weeks as doses increased.

About 7% of people in major semaglutide trials discontinued due to side effects. For tirzepatide, discontinuation rates ranged from 4.3% to 8.5% depending on the dose.

If you're experiencing severe side effects, don't just try to optimize your behavior. Talk to your healthcare provider about dose adjustments or alternative medications. Some people need slower escalation schedules or different GLP-1 formulations.

The idea that side effects are primarily user error minimizes legitimate medication reactions and could discourage people from seeking appropriate medical guidance when they need it.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

My Journey with Marc · TikTok creator

55.4K views on this video

#GLP1 side effects on #Mounjaro or #wegovy. Here’s the most common mistakes people make that cause them.

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 44% of people taking 1.0mg semaglutide in the sustain 1?

44% of people taking 1.0mg semaglutide in the SUSTAIN 1 trial experienced nausea, showing side effects aren't primarily user errors

What does the video say about tirzepatide caused nausea in 31% of patients at 15mg in?

Tirzepatide caused nausea in 31% of patients at 15mg in the SURMOUNT-1 trial despite careful dose escalation protocols

What does the video say about glp-1 medications slow gastric emptying as part of their mechanism,?

GLP-1 medications slow gastric emptying as part of their mechanism, making some digestive side effects unavoidable

What does the video say about gradual dose increases starting at 0.25mg semaglutide?

Gradual dose increases starting at 0.25mg semaglutide or 2.5mg tirzepatide help minimize but don't eliminate side effects

What does the video say about about 7% of semaglutide users?

About 7% of semaglutide users and 4.3-8.5% of tirzepatide users discontinue due to side effects in clinical trials

What does the video say about eating smaller meals, limiting alcohol,?

Eating smaller meals, limiting alcohol, and staying hydrated can help manage GLP-1 side effects

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by My Journey with Marc, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.